Our mission is to deliver solutions and bring hope to as many people as possible.

Biosimilar medicines enable us to do so, by ensuring access to treatments and contributing to the sustainability of healthcare systems worldwide.

More info

Growth driven by passion and commitment, enabling us to enter any market and adapt to challenges with dedication and talent.

More info

Trust built on the values and the experience of a dynamic, multi-disciplinary and highly qualified team.

The application of a unified work methodology, with a focus on quality in everything we do.

More info

 

Our mission is to deliver solutions and bring hope to as many people as possible.

Biosimilar medicines enable us to do so, by ensuring access to treatments and contributing to the sustainability of healthcare systems worldwide.

More info

 

Growth driven by passion and commitment, enabling us to enter any market and adapt to challenges with dedication and talent.

More info

 

Trust built on the values and the experience of a dynamic, multi-disciplinary and highly qualified team.

The application of a unified work methodology, with a focus on quality in everything we do.

More info

ABOUT
mAbxience

mAbxience is a high growth international biotechnology company specialized in the research, development, manufacture and global commercialization of biopharmaceutical products to treat and prevent diseases across different therapeutic areas.

mAbxience is a fully integrated biopharmaceutical company specialized in research, development and manufacturing of biosimilars for the treatment and/or prevention of several diseases in diverse therapeutic areas.

Partnerships

mAbxience has successfully established alliances around the world with key partners, allowing patients access to our quality products across the globe.

We work to ensure supply of affordable medicines to health care systems worldwide, adapting to the needs of each regulatory and commercial environment.

mAbNews

ESMO publication: EMA grants a marketing authorisation for two biosimilar medicines, bevacizumab

02/15/2021

They received a positive opinion for the treatment of carcinoma of the colon or rectum, breast cancer, NSCLC, RCC, epithelial ovarian cancer, and carcinoma of the cervix

Spanish group Insud Pharma signs agreement with AstraZeneca to manufacture COVID-19 vaccine candidate

01/20/2021

The plant in Spain’s Castilla-La Mancha region will undertake vial filling and packaging for AZD1222 The company also provides drug substance manufacturing for AZD1222 through their site in Argentina Insud Pharma is at the forefront of Spanish companies in investment in R&D The Spanish pharmaceutical group Insud Pharma will provide vial filling and packaging of […]

mAbxience enters into an agreement with AstraZeneca to produce Covid-19 vaccine

08/17/2020

mAbxience, the biotec company of the Spanish Insud Pharma group, is deeply proud to announce that has entered into an agreement with AstraZeneca to produce a Covid-19 vaccine in Latin America. Our recently inaugurated plant in Garín (Argentina) will produce the active ingredient, which will subsequently be sent to Mexico to complete the production and […]

mAbxience is a Spanish fully-fledged biotech company with a decade of experience in developing and manufacturing biosimilars.

Part of the Spanish multinational Insud Pharma (formerly Chemo), a group with +40 years of experience, more than 6,000 professionals and presence in 40 countries around the world.

Bio-Europe Spring 2021

Meet us at Bio-Europe Spring, to be held 22-25 March. 2021.

+

Our business model is B2B (business to business), with global partnership network of key market leaders in the EU, US, Japan and emerging markets.

+